Long-term effects of rhEPO therapy on erythrocyte rheology in dialysis patients with different target hematocrits.
Successful treatment of renal anemia with recombinant erythropoietin (rhEPO) raises the question of whether the renal anemia symptom complex requires complete correction. Current arguments against increasing hemoglobin (Hb) levels above 10-11 g/dl are impaired hemodynamics, increased risk of vascular access occlusion, unmanageable hypertension and dialysis complications. The aim of the study was to determine whether sustained Hb normalization using long-term rhEPO causes hemorheological changes with a potentially negative hemodynamic impact. The study was conducted in 42 rhEPO-treated dialysis patients with stable Hb > 11.0 g/dl for at least 20 weeks. The mean Hb of the total study group was 12.8 1.1 g/dl. To study the effect of Hb as a risk indicator in greater detail, the patients were divided into two groups, with hematocrits above and below 0.40. Hemorheology (erythrocyte deformability and aggregation, plasma viscosity) showed no significant changes, including vs a healthy control group. Throughout the period of increased rhEPO administration, no increase was observed in the incidence of hypertension or vascular thrombosis.


CONCLUSIONS
the marked additional quality-of-life benefit achieved by complete correction of renal anemia harbors no substantial increase in treatment risk.
Paulitschke
M
M
Cell-Lining GmbH, Berlin, Germany.
Ludat
K
K
Riedel
E
E
Hampl
H
H
D000328:Adult; D000368:Aged; D001809:Blood Viscosity; D004907:Erythrocyte Deformability / Q000187:drug effects*; D004921:Erythropoietin / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006400:Hematocrit; D018056:Hemorheology / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D006435:Renal Dialysis; D013997:Time Factors
D011994:Recombinant Proteins; D004921:Erythropoietin